US drug pricing legislation that has picked up momentum could stymie R&D investment and curb the revenue tail for some big drugs, industry says, but CEOs also expect they can navigate the challenge. 

MAXVAX Biotechnology and Beijing Luzhu Biotechnology raise new funds to progress their recombinant herpes zoster vaccine candidates with novel adjuvants, while multiple other ventures in China complete new financings across multiple therapeutic areas and modalities. 

Vertex is expanding its investments across advanced therapies again, R&D chief David Altshuler adding a second in vivo gene-editing deal to its pipeline.

Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.